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Abstract  Human immunodeficiency virus (HIV) infection is associated with an 
increased risk for Viral infections such as Epstein-Barr virus (EBV)infections 
also known as Human Herpes Virus Type 4 (HHV-4) and their related diseases 
which frequently cause malignancy related diseases resulting to poor treatment 
and health outcomes. In this study, we determined the seroprevalence of EBV 
VCA IgM antibodies among HIV patients attending Plateau Specialist Hospital, 
Jos, Nigeria and to evaluate their association with age, sex as well as other 
demographic factors. A total of 92 HIV positive patients were enrolled and serum 
samples were screened for antibodies using the ELISA kit. The prevalence of 
EBV VCA IgM was 6/92(6.53%), and mean age of 37.48 ±1.01 years. This study 
has contributed to baseline data, and suggest the need for larger studies and 
importance of screening and treatment of EBV among HIV patients. 
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1. Background 
Epstein-Barr virus (EBV) also known as Human Herpes virus type-4 (HHV-
4) belongs to the family of herpesviridae,  Subfamily Gammaherpesvirinae, 
Genus Lymphocryptovirus and serves as the dominant cause of acute infectious 
mononucleosis in young children and adolescents [1], with about 90% of adults 
in the world have antibodies against EBV [2]. Primary acute EBV infections are 
largely asymptomatic and the latent infection could persist for the lifetime [3].  
In few circumstances, chronic active EBV infections might lead to 
complications and death in immunosuppressed individuals [4]. EBV infections 
have been linked to hemophagocytic syndrome, a severe inflammatory illness, 
characterized by prolonged fever, cytopenia, and liver dysfunction [5,6]. Additionally, the virus is causally linked to several 
other malignancies, such as Burkitt’s lymphoma, Hodgkin lymphoma, tumors in HIV-infected patients, and nasopharyngeal 
carcinomas [7-9]. Previous studies have estimated the sero-epidemiology in Europe and United States to be over 50% of 
adolescents would have been seropositive to EBV [10,3,11]. However, studies in Africa (Ethiopia and Nigeria) and Asia 
(Taiwan) have reported seroprevalence from 6%, 11% -17% [12-15], but data on the sero-epidemiology of EBV among 
HIV infected is still very scarce in Nigeria. 
Several factors and analysis of risk factors such as;  age, gender, country or region of residence, household educational 
level, kissing, smoking habit and sexual activity have been associated with the EBV seropositivity [16,17]. The use of 
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vaccination which is unavailable along with other public health measures can greatly reduce the co-morbidity burden of 
EBV infection among immunosuppressed individuals. The sero-epidemiological data would provide useful information for 
public health interventions towards target populations and development of an idea candidate vaccine. It is well known that 
EBV is a common opportunistic infection agent in the human immunodeficiency virus-infected individuals who are 
immunocompromised. In this study we conducted a small-scale study to describe the prevalence of specific antibodies 
(IgM) to EBV-VCA and demographic factors in Jos Nigeria. 
2. Materials and Methods 
2.1. Study Population 
The HIV positive individuals attending plateau state specialist hospital Jos, Plateau State, Nigeria who consented were 
enrolled from October to December 2017. The patients bio data including clinical (CD4) and other relevant information 
were obtained using structured questionnaire and were assured of strict confidentiality of responses as specified in the 
ethical clearance guideline given for this study. Afterwards, blood sample was collected from each of the 92 enrolled 
patients. The study protocol was approved by Ethics Committee of Plateau State Specialist Hospital Jos, Plateau State 
according to the amended 1964 Helsinki Declaration. 
2.2. Sample Collection 
Blood samples were collected in tube with anticoagulant for serology. A tourniquet was firmly tied to the upper arm of 
the subjects while sitting and the skin was sterilized with 70% alcohol. The vacutainer needle was inserted into conspicuous 
antecubital vein and the plunger of the sterile syringe was withdrawn and pressure applied to the puncture site and apply 
dry cotton wool to stop bleeding and tubes were labelled appropriately. Blood samples were spun on a bench centrifuge at 
3,000 rpm for 10 minutes to obtain sera. Aliquots of serum were made per sample in labelled sterile cryovials which were 
stored at −20°C until ready for analysis. 
2.3. Qualitative testing of anti- EBV IgM antibodies 
The commercial enzyme-linked immunoassay (ELISA) kit Golden Bio Technologies Corp, CA 91786, U.S.A was used 
to detect anti-EBV viral capsid antigen (VCA) IgM in sera. The assay was performed in accordance with manufacturer’s 
instruction. Briefly, the diluted patient serum was added to wells coated with purified antigen, and the plate was incubated 
with 100μl of diluted serum at room temperature for 30 minutes. After washing for three times, peroxidase-conjugated anti-
human IgM was added and incubated at room temperature for 30 minutes. After another washing for three times, the plate 
was incubated at room temperature for 15 minutes to allow the hydrolysis of the substrate by the Enzyme. The kit provided 
ready-to-use positive controls negative controls and calibrators ((IgM, human). Excess enzyme conjugate is washed off and 
substrate is added. The reaction was stopped and the optical density was measured at 450nm. The intensity of the color 
generated is proportional to the amount of IgM specific antibody in the sample. The standard curve was established by 
calibrators and used to calculate virus-specific antibody concentration, and the result was interpreted according to the 
manufacturer’s instruction. 
2.4. Statistical Analysis 
The data obtained from the study were subjected to descriptive statistical analysis. Statistical analysis of results was done 
using SPSS 20.0 statistical software. Chi square was used and P<0.05 was considered to be significant. Adjusted odd ratio 
was used to determine the association between the infection and the risk factors.  SPSS program for Windows (V.21.0; 
SPSS, Inc., Chicago, IL) was used. 
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3. Result 
Total of 92 patients were enrolled, 6 were positive for EBV-VCA IgM antibodies, therefore the prevalence of EBV 
infection among HIV infected patients in Jos Metropolis was 6.53% as summarized in Table 1 showing the mean age of 
patients was 37.48 ±1.01 years. The table also showed summary of the distribution of EBV infection among age groups, 
sex, marital, employment, educational, duration of ART and CD4 status of the individuals. High prevalence (7.50%) was 
observed among the age group of 31-40 years with no significance difference (p=0.13). in the sex category, the prevalence 
among the female was 8.51%, male (4.45%) p=0.76, while the marital status, the prevalence was high among the widowed 
(7.70%), single/separated (5.46%), married (5.89%), with no significance difference (p=0.42). For the employment status, 
the prevalence was high among the unemployed group (8.16%), employed (4.65%), p=0.82, while the prevalence among 
the duration on ART; 0-1 years (11.43%, 2-4 years (6.67%), ≥5 years (2.38%), p= 0.68. For the educational status; the 
prevalence was high among those with secondary school (8.00%), Primary (6.38%), tertiary (5.00%), p=0.68. Based on the 
CD4, the patients were into two; <500, and ≥500, the prevalence was higher among the former category (7.94%), with no 
significance difference (p=0.062). There was no statistical difference in the seroprevalence of EBV-VCA IgM antibodies 
between the subgroups. 
Table 1. Prevalence of EBV IgM infection in relation to Age, Sex, marital, employment, duration of ART, 
Educational and CD4 Status among HIV infected patients. 
Characteristic  No Patients  NO. Positive (%) P- value  
Age   0.13 
18-30  18(19.56) 1(5.55)    
31-40  44(43.48)  3(7.50)  
41-50 25(27.17) 1(4.00)  
≥ 51 19(20.65) 1(5.26)  
Sex    0.76 
Male 45(48.91) 2(4.45)  
Female  47(51.09) 4(8.51)  
Marital status                                             0.42 
Married  34(36.96)  2(5.89)   
Single/Separated 55(59.78) 3(5.46)  
Widowed  13(14.13) 1(7.70)  
Employment status   0.82 
Employed  43(46.74) 2(4.65)  
Unemployed 49(53.26) 4(8.16)  
Duration on ART   0.68 
0-1 Years 35(38.05)  4 (11.43)  
2-4 Years  15(16.31) 1(6.67)  
≥ 5 Years 42(38.29) 1(2.38)  
Educational Status   1.09 
 47(51.09) 3(6.39)   
Secondary 25(27.18) 2(80.00)  
Tertiary 20(21.74)  1  
CD4 Count.   0.06 
<500 63(68.48) 5(7.94)  
≥500 29(31.53) 1(3.45)  
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4. Discussion 
Epstein Barr virus is one of the leading cause of comorbidity and malignancies such as Burkitt ś lymphoma and 
nasopharyngeal carcinoma in HIV-positive individuals due to immunosuppression. EBV has been identified as a major 
contributing factor to the pathogenesis of most of lymphoproliferative diseases, including Orapharyngeal and leukoplakia 
in HIV positive patients [5]. The presence of anti-VCA IgM antibodies shows acute primary EBV infection which are 
usually produced transiently in the early course of illness and disappear within 4 to 6 weeks [18]. The appearance of EBV 
VCA IgM in HIV positive individuals indicate the presence of the virus and suggestive of acute infection [19]. Though the 
symptomatic status of EBV infection was not established in the study population, but it was unclear about the level of 
subclinical EBV infections and its role in the transmission of virus in the Nigerian population. To better understand the 
interaction among the age of EBV acquisition, the development of either symptomatic or subclinical illness, and the risk of 
EBV-associated malignancies, further longitudinal studies is suggested to address the epidemiology in the HIV population 
and the immune correlate of protection against virus.  
The observed prevalence (6. 53%) was high compared to earlier study done in south west Nigeria which recorded 4% 
[13], but similar to another finding in Zaria, Northern Nigeria with prevalence of 6.6% [12]. The highest prevalence of anti-
EBV IgM (5.81%) was in the age range (31-40) years. This may be due high sexual activities and networking amongst 
other factors such as assayed antibody type, geographical location as well as low living standard of the study population as 
compared to the age range mentioned in earlier reports, and its corroborates with earlier reported studies [20,21] that age 
range 21-40 and 30 ≤ 40 have the highest EBV antibody incidence, respectively. The prevalence was higher among the 
females, however, with no significance and this was agreement with other reported studies [22,23]. Although underlined 
mechanisms involving high EBV antibodies in females remain unclear, but the reason could be frequent contacts with 
children than men. 
The sero-epidemiological pattern of EBV infection which is obvious with other infectious diseases could be affected by 
different factors such as; the public health policy, sexual practice, hygiene behavior, and socio-economic status. In the 
study, we observed high prevalence among the widows, unemployed secondary level of education and those who are on 
ART less than 1 year, but with no statistical significance, although the definition of these factors could vary in different 
population and countries. We observed that CD4 cell count was associated with the EBV seropositive rate in Nigeria, this 
corroborated with recent study done by Abdollahi et al. (2014), which suggested that low CD4+ cell count may be an 
indication of poor clinical outcomes. This in effect, may have higher chances of associated malignancies and or other 
opportunistic infections. Though the low CD4+ cell count (<500 cells/mm3) observed had no significant association, and 
this was corroborated with earlier reported studies [12,21]. This may also be due to transmission pattern proposed of adults 
acquiring higher viral dose through sexual activity than children do through salivary contact [17,24]. Taken together, low 
CD4+ cell count may suggest poor outcome of HIV infection as mentioned earlier [21]. 
This study bears some limitation such as the study design and small sample size which may not permit generalization of 
our findings. Future larger and multicenter clinical research are suggested to address some unanswered sero-
epidemiological questions. 
Conclusion 
The current study showed high of EBV anti-EBV IgM in HIV-positive patients, and with the causal link of EBV and 
certain lymphoma associated malignancies in HIV positive adults. This data suggest that there may be cases of infectious 
mononucleosis among populations at risk such as HIV infected   and that clinicians and other healthcare should look out 
for it. In view of this screening strategies and awareness by non-profit organizations and healthcare workers should be put 
in place for early detection and prompt antiviral treatment. Also awareness on hygiene practices as preventive methods to 
reduce infection rates in the general and risk population. The development of effective and use of EBV vaccine could 
substantially reduce the disease burden due to primary EBV infection and incidence of infectious mononucleosis and 
associated human malignancies such as Hodgkin's disease, endemic Burkitt's lymphoma, and nasopharyngeal carcinoma. 
Further larger study is needed to investigate both prevalence and incidence among the general and target populations. 
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